SubscribeLatest 5 articles from heartwire
- Air pollutants mediate effects on heart health through inflammation and thrombosis
May 17, 2012 17:15 EDT - Azithromycin may up chance of sudden cardiac death
May 16, 2012 17:00 EDT - So long, Plavix, what a ride! Clopidogrel patent expires
May 16, 2012 14:45 EDT - COMFORTABLE-AMI: Bioerodable polymer DES trumps bare metal in STEMI
May 16, 2012 10:50 EDT - COMPARE II: Nobori biolimus stent matches everolimus stents in all-comers
May 16, 2012 10:15 EDT
#84: TAVI matches surgery in PARTNER cohort A; PARTNER B cost-effectiveness; MAGELLAN on rivaroxaban in acute medical patients; EVEREST II: MitraClip less effective but safer than surgery; STICH on CABG in HF patients; EXCELLENT on duration of DAPT
Please note that the audio will stop and restart at the beginning of the file when submitting a comment.
Veuillez notez que le fichier audio s’arrête et recommence au début lorsqu’un commentaire est publié.
DOWNLOAD
Download this episode in your preferred format:
For the week ending April 8, 2011 we discuss the following top cardiology news from the American College of Cardiology 2011 Scientific Sessions:
- PARTNER cohort A: Transcatheter valves noninferior to surgery
- TAVI cost-effective treatment in surgery-ineligible patients: PARTNER cohort B cost analysis
- MAGELLAN: Rivaroxaban prevents VTE in medical patients, but bleeding an issue
- Latest from EVEREST II: MitraClip less effective but safer than surgery
- Docs say STICH "hypothesis one" supports CABG in HF patients despite missing primary end point
- EXCELLENT results for stopping DAPT at six months, but others say bigger trials are needed
Join us for a comprehensive review of this week's most important cardiology news.
Previous posts
#140: Ideal blood-pressure goals? "We have no idea"; more adverse events seen on dabigatran vs warfarin; WHF defends Dubai WCC, reimburses Israelis denied visas; Roche stops dalcetrapib trial; bypass moderate coronary lesions? taking sides in the debate
No comments |
Posted May 11, 2012
at 11:40 AM, EDT by Steven
at 11:40 AM, EDT by Steven
#139: CHA2DS2-VASc score gives best prediction of stroke risk in AF; subcutaneous ICD: thumbs up from FDA; DES or bare-metal stents for primary PCI?; beware valve involvement in device-related infective endocarditis; CMS restricts TAVI coverage to experie
No comments |
Posted May 04, 2012
at 01:40 PM, EDT by Steven
at 01:40 PM, EDT by Steven
#138: FDA: No aliskiren with ACE inhibitors, ARBs in some patients; cardiologists: high income, many frustrations; TIPS 2 on full-dose polypill; ESC paper on new anticoagulants; Bahrain AED survey points to CPR barriers
No comments |
Posted Apr 27, 2012
at 01:00 PM, EDT by Steven
at 01:00 PM, EDT by Steven
#137: Big bonuses for cardiologists at OSU; higher glycated hemoglobin levels, better outcomes in HF with diabetes; losartan vs candesartan mortality risk in HF disputed; Italian soccer player dies on the pitch; Maryland to set up independent PCI review
No comments |
Posted Apr 20, 2012
at 03:00 PM, EDT by Steven
at 03:00 PM, EDT by Steven
Also from theheart.org
About This week in cardiology from heartwire
Published each Friday, this podcast delivers the week's five most popular articles in audio format. On the go? Take heartwire with you and stay on top of the latest in cardiology news, wherever your week takes you.
Comments